Your search returned 9 results.

Results
	1.	Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials. [electronic resource] by Farlow, M R Cyrus, P A Producer: 20000816 In: Dementia and geriatric cognitive disorders vol. 11 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living. [electronic resource] by Gélinas, I Gauthier, S Cyrus, P A Producer: 20000518 In: Journal of geriatric psychiatry and neurology vol. 13 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group. [electronic resource] by Blass, J P Cyrus, P A Bieber, F Gulanski, B Producer: 20000404 In: Alzheimer disease and associated disorders vol. 14 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease. [electronic resource] by Cummings, J L Nadel, A Masterman, D Cyrus, P A Producer: 20011101 In: Journal of geriatric psychiatry and neurology vol. 14 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. [electronic resource] by Raskind, M A Cyrus, P A Ruzicka, B B Gulanski, B I Producer: 19990611 In: The Journal of clinical psychiatry vol. 60 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group. [electronic resource] by Cummings, J L Cyrus, P A Bieber, F Mas, J Orazem, J Gulanski, B Producer: 19980608 In: Neurology vol. 50 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	Metrifonate treatment of AD: influence of APOE genotype. [electronic resource] by Farlow, M R Cyrus, P A Nadel, A Lahiri, D K Brashear, A Gulanski, B Producer: 20000104 In: Neurology vol. 53 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group. [electronic resource] by Jann, M W Cyrus, P A Eisner, L S Margolin, D I Griffin, T Gulanski, B Producer: 19990512 In: Clinical therapeutics vol. 21 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. [electronic resource] by Morris, J C Cyrus, P A Orazem, J Mas, J Bieber, F Ruzicka, B B Gulanski, B Producer: 19980608 In: Neurology vol. 50 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)